A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
Completed · Phase 2 · Has a placebo group
Conditions studied: Overweight or Obesity
In brief
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Key facts
- Study ID
- NCT06854952
- Run by
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- People needed
- 167
- Starts
- 2025-03-07
- Expected to finish
- 2025-09-19
- Last updated by the study team
- 2025-11-06
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- FALCON Research Site — Birmingham, Alabama, United States
- FALCON Research Site — Homewood, Alabama, United States
- FALCON Research Site — Tucson, Arizona, United States
- FALCON Research Site — Spring Valley, California, United States
- FALCON Research Site — Port Orange, Florida, United States
- FALCON Research Site — Louisville, Kentucky, United States
- FALCON Research Site — Marrero, Louisiana, United States
- FALCON Research Site — Boston, Massachusetts, United States
- FALCON Research Site — Rochester, Minnesota, United States
- FALCON Research Site — City of Saint Peters, Missouri, United States
- FALCON Research Site — Beachwood, Ohio, United States
- FALCON Research Site — Medford, Oregon, United States
- FALCON Research Site — Dallas, Texas, United States
- FALCON Research Site — Houston, Texas, United States
- FALCON Research Site — San Antonio, Texas, United States
- FALCON Research Site — St. George, Utah, United States
- FALCON Research Site — Arlington, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.